1.Department of Oncology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530011, China;
2.Department of Cardiology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530011, China
Abstract：Objective To systematically evaluate the efficacy of Chaishao Liujunzi Decoction combined with transarterial chemoembolization (TACE) in the treatment of primary liver cancer.Methods The Chinese and English literature databases were searched by computer, and randomized controlled studies (RCTs) of Chaishao Liujunzi Decoction combined with TACE (experimental group) and TACE (control group) on patients with advanced primary liver cancer were searched.The retrieval time was from the time of building the repository to November 30, 2019.RevMan 5.3 software was used for Meta-analysis.Results The Meta-analysis showed that the Karnofsky performance status (KPS) score of the experimental group was higher than that of the control group (MD=9.43, 95%CI=6.59-12.27, P＜0.000 01), the increase of bilirubin was lower than that of the control group(RR=0.48,95%CI=0.31-0.74,P=0.001),the nausea and vomiting was lower than that of the control group(RR=0.54,95%CI=0.31-0.94,P=0.03),the abdominal pain was lower than that of the control group (RR=0.56, 95%CI=0.40-0.79, P=0.001), and the fever was lower than that of the control group (RR=0.60, 95%CI=0.42-0.85, P=0.005), and the differences were statistically significant.There were no significant differences in solid tumor control (RR=1.04, 95%CI=0.93-1.17, P=0.48), leukopenia (RR=0.76, 95%CI=0.48-1.20, P=0.24)and thrombocytopenia (RR=0.81, 95%CI=0.52-1.24, P=0.32) between the two groups.Conclusion Chaishao Liujunzi Decoction combined with TACE can significantly improve KPS score and reduce the occurrence of adverse reactions to chemotherapy.
Abdel-Rahman O，Elsayed ZA.Combination trans arterial chemoembolization（TACE） plus sorafenib for the management of unresectable hepatocellular carcinoma：a systematic review of the literature[J].Dig Dis Sci，2013，58（12）：3389-3396.
Bruix J，Sherman M，American Association for the Study of Liver Diseases.Management of hepatocellular carcinoma：an update[J].Hepatology，2011，53（3）：1020-1022.
[6]
Strobel O，Büchler MW.Treatment effect of liver resectionvs.RFA or TACE in hepatocellular carcinoma[J].Chirurg，2019，90（Suppl 2）：75.
[7]
Johnson BW，Wright GP.Regional therapies for the treatment of primary and metastatic hepatic tumors：A diseasebased review of techniques and critical appraisal of current evidence[J].Am J Surg，2019，217（3）：541-545.
京公网安备 11010502046607号